Safety
A total of 35 subjects received study drug at least once, and 10 of them reported 20 AEs. Among reported AEs, 12 AEs were evaluated as drug-related by the investigators (Table 4). A total of 13 AEs, 3 AEs and 4 AEs were reported after EVO, PIO, and EVO+PIO, respectively. All AEs were spontaneously recovered during the study period, except for one case of lip blister which was recovering during to follow-up period. No serious AEs or clinically significant findings in vital signs, physical examinations, clinical laboratory tests and ECGs were reported.